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Abstract
The cytokine “macrophage migration inhibitory factor (MIF)" is generally recognized as a proinflammatory cytokine, 
and MIF is involved in broad range of acute and chronic inflammatory states. With regard to glucose metabolism 
and insulin secretion, MIF is produced by pancreatic β cells and acts as a positive regulator of insulin secretion. In 
contrast, it is evident that MIF expressed in adipose tissues causes insulin resistance. Concerning MIF gene analysis, 
we found four alleles: 5-, 6-, 7- and 8-CATT at position −794 of MIF gene in a Japanese population. Genotypes without 
the 5-CATT allele were more common in the obese subjects than in the lean or overweight groups. It is conceivable 
that promoter polymorphism in the MIF gene is profoundly linked with obesity relevant to lifestyle diseases, such as 
diabetes. Obesity has become a serious social issue due to the inappropriate nutritional balance, and the consumption of 
functional foods (including functional foods to reduce fat mass) is expected to overcome this issue. In this context, MIF 
would be a reliable quantitative biomarker to evaluate the effects of functional foods on adiposity.
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Introduction
A number of cytokines called adipokines that are 
expressed in adipocytes are involved in diabetes, 
hypertension, and other lifestyle-linked diseases. A 
cytokine known as macrophage migration inhibitory 
factor (MIF) was originally identified as a cytokine 
produced by activated T cells (Bloom & Bennett, 1966; 
David, 1966). MIF was found to be secreted from 
monocytes and macrophages as major sources (Calandra 
et al., 1994), and has the potential to exacerbate 
endotoxin shock (Bernhagen et al., 1993; Bucala, 1996). 
A number of pathophysiological roles of MIF have 
been described. MIF functions as an essential mediator 
in T-cell activation (Bacher, 1996) and delayed-type 
hypersensitivity (Bernhagen et al., 1998). We cloned rat 
MIF cDNA and elucidated its tertiary protein structure 
by X-ray crystallography, and we reported a number of 
physicochemical properties of this cytokine (Nishihira, 
1998; Nishihira, 2000).
By immunohistochemical analysis, MIF was observed 
in the cytosol of immune cells such as macrophages, 
and also in adipocytes (Hirokawa, 1997) and pancreatic 
cells (Waeber et al., 1997). It is generally accepted 
that adipocytes are not only an energy deposit but also 
secrete a variety of bioactive molecules such as leptin, 
plasminogen activator inhibitor-1, and tumor necrosis 
factor (TNF)-α (Weisberg et al., 2003). In particular, 
the TNF-α expression of adipocytes was found to 
be increased in obese patients, and TNF-α exerts an 
inhibitory effect on the insulin signal transduction 
system, resulting in insulin resistance (Hotamisligil 
This is an open access article under the CC BY-NC-ND license.
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et al., 1993; Hotamisligil et al., 1995). Since obesity 
is associated with a chronic inflammatory response, 
MIF may have an impact on the pathophysiology of 
adiposity. The findings regarding adipose tissue and 
functional molecules prompted us to investigate the role 
of MIF in diabetes and obesity.
Among the various functions of MIF, we first focused 
on the issue of MIF mRNA in adipose tissues in 
response to glucose and insulin. We confirmed that MIF 
plays an important role in glucose metabolism and its 
related diseases. In this review, we discuss the biological 
characteristics of MIF, focusing on diabetes and obesity 
and the functionality of the MIF gene with respect to 
promoter polymorphisms in association with adiposity. 
We also discuss the potential role of MIF as a biomarker 
for the evaluation of pharmaceuticals and functional 
foods applicable for the amelioration of a pandemic 
lifestyle disease, e.g., obesity.
The pathophysiological role of MIF in 
adipocytes
Expression and Regulation of MIF in Adipocytes
First, we investigated whether glucose and insulin 
could stimulate MIF mRNA expression in 3T3-L1 
adipocytes in vitro. In brief, MIF mRNA was markedly 
enhanced, reaching the maximum level at the dose of 
1 μg/ml insulin with a 2.8-fold increase in the presence 
of 400 mg/dL glucose (Sakaue et al., 1999). In contrast, 
no significant increase was observed in the presence 
of 100 mg/dL glucose. These findings show that 
concomitant stimuli of high glucose level and insulin 
are essential for the up-regulation of MIF mRNA.
Following this experiment, we quantitated the 
intracellular MIF protein content in response to 
insulin. After a 24-hr incubation of mouse adipocytes 
in the presence of various concentrations of glucose 
and insulin, aliquots of cell lysates were collected, 
and the MIF concentration was measured with an 
ELISA (enzyme-linked immunosorbent assay). The 
results revealed that the intracellular MIF protein 
level increased in parallel with the up-regulation of 
MIF mRNA. In contrast, the MIF concentration in the 
cell culture medium decreased when the adipocytes 
were stimulated with both glucose and insulin. Thus, 
we concluded that the intracellular content of MIF in 
adipocytes increases in response to insulin and glucose, 
whereas the extracellular release of MIF is taken up by 
the cells and stored within them. The precise mechanism 
is not well understood, but MIF could be used as a 
recycling bioactive molecule between intracellular and 
extracellular spaces.
As for insulin secretion from pancreatic β cells, it 
was demonstrated that anti-MIF antibody administration 
suppressed insulin secretion from these cells following 
the glucose challenge (Waeber et al., 1997). We 
hypothesized that MIF produced by pancreatic β cells 
acts as a positive regulator of insulin secretion in both 
an autocrine and paracrine manner. Elevated insulin 
may stimulate the up-take of glucose by adipocytes. 
However, some of pro-inflammatory cytokines, e.g., 
interleukin-6 can cause insulin resistance in concert 
with TNF-α. In our understanding, MIF appears to 
play dual roles; that is, positive and negative functions 
in the regulation of the serum glucose level. In this 
context, it is critical to elucidate the mechanisms of 
how MIF is secreted in the extracellular space. When 
such mechanisms are identified, the pathophysiological 
roles of MIF in glucose intolerance will be more clearly 
understood.
The abnormal production of proinflammatory 
cytokines (such as TNF-α) in adipose tissue has been 
reported in obese rodents (Xu et al., 2003) and humans 
(Norman et al., 1995). The dysregulation of cytokines 
could contribute to the insulin resistance often seen in 
obesity. MIF is known as a pro-inflammatory cytokine, 
and it exacerbates the inflammatory reaction in 
concert with TNF-α. Regarding the pathophysiological 
actions of MIF, further insight into the local and 
systemic actions of MIF is necessary for a complete 
understanding of the functions of this molecule in 
diabetes and obesity.
We hypothesize that MIF functions to stimulate 
insulin secretion from pancreatic β cells in a local 
tissue-specific manner that controls the serum insulin 
level, whereas MIF secreted from macrophages or 
other cells circulating through the entire body would 
enhance insulin resistance together with TNF-α. We 
hypothesized that MIF bi-functionally regulates insulin 
availability and functionality in a positive manner for 
insulin secretion in pancreas, and in a negative manner 
for insulin resistance in adipose tissues.
MIF mRNA Expression in aAdipose Tissue in vivo
We also elucidated the characteristics of MIF in 
adipose tissues obtained from rats. In contrast to the 
findings with cultured adipocytes, MIF mRNA was 
significantly down-regulated in the adipose tissues 
(epididymal fat pads) of two different animal models, 
noninsulin-dependent diabetes mellitus (NIDDM)-
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Otsuka Long-Evans Tokushima fatty (OLETF) rats 
and Wistar fatty rats (Sakaue et al., 1999). Although 
the reasons for the decreased MIF mRNA levels in 
fat tissues are unclear, this result suggests a possible 
biological link between the expression level of MIF 
and the severity of obesity and diabetes. To investigate 
this in detail, we examined the profile of MIF mRNA 
expression of primary adipocytes obtained from rats.
Expression of MIF mRNA in Primary Culture Cells
To examine the relationship between MIF expression 
levels and the severity of adiposity, we measured 
MIF mRNA expression in cultured rat primary cells 
at regular intervals through day 9 after the initiation 
of cell culture. The MIF mRNA expression increased 
depending on the time of incubation and reached a 
maximum at a certain time interval (day 6), but the 
expression gradually decreased when the cells became 
overgrown (Figure 1). This in vitro experiment may 
explain the down-regulation of MIF mRNA expression 
observed in the excessive obese state of OLETF rats. We 
also observed that the profile of MIF mRNA expression 
was similar to that of adiponectin mRNA. The profile 
of leptin mRNA increased as the cells grew. These 
data indicate that MIF plays an important role in the 
regulation of the cytokine network system of adipocytes 
in concert with adiponectin in a positive or negative 
manner, but this needs further investigation.
Effect of Pioglitazone on the MIF Secretion of 
Adipocytes
Pioglitazone is known as an antidiabetic agent and has 
a pharmacological action to improve insulin resistance. 
We clarified the effect of pioglitazone on MIF mRNA 
expression and MIF protein production by adipocytes 
(Sakaue et al., 1999). When the adipocytes were 
incubated with pioglitazone (5 µM) for 24 hr, the MIF 
protein content in the culture medium was increased to 
about two fold that of the untreated cells, whereas the 
MIF mRNA expression level was minimally changed. 
This result shows that pioglitazone has the potential to 
enhance MIF secretion from adipocytes. We hypothesize 
that pioglitazone improves insulin resistance in part 
by stimulating the release of MIF into the extracellular 
space. Taken together, the relevant findings indicate 
that MIF may have a key role as a positive regulator of 
insulin secretion from pancreatic β cells, which would 
ameliorate, at least in part, insulin resistance together 
with pioglitazone. In this context, as mentioned above, 
the functions of MIF in terms of glucose metabolism 
should be determined at the local level, e.g., pancreatic 
cells regarding insulin secretion and at the systemic 
level, e.g., insulin resistance.
Promoter Polymorphism in the MIF Gene 
in Association with Adiposity
Analysis of the MIF Gene in Association with Obesity
Obesity is an independent risk factor for a wide 
variety of diseases, especially lifestyle diseases, 
diabetes, hypertension, and hyperlipidemia. As the 
morbidity of these diseases is increasing, obesity has 
become a serious health problem not only in western 
countries but also in Asia, especially Japan, China, and 
Korea. A high-calorie and high-fat diet and a sedentary 
lifestyle contribute to the development of obesity. It is 
evident that genetic factors also play an important role 
Figure 1. MIF mRNA expression of rat primary adipocytes.Pre-
adipocytes collected from abdominal fat tissue of rats were harvested 
and cultured for 9 days, and the mRNA expressions of MIF, 
adiponectin and leptin were measured by real-time PCR at daily 
intervals.
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in adiposity. Several studies of the relationship between 
body mass index (BMI) and gene polymorphisms 
have been reported, and the gene polymorphisms have 
been widely used as biomarkers for the severity of 
adiposity. It has also become clear that any promoter 
polymorphisms of the MIF gene relevant to obesity 
would be useful to account for the entire genetic 
contribution to obesity (Sakaue et al., 2006).
The MIF gene is located on chromosome 22q11.23, 
which was found to be associated with abdominal 
obesity in Caucasians in a genome-wide linkage 
scan (Rice et al., 2002). This finding suggested that 
this chromosomal region is a susceptibility locus for 
abdominal adiposity in a particular population, such 
as Japanese. Polymorphism has been identified within 
the promoter region of the MIF gene, a tetranucleotide 
CATT repeat located at position −794 (−794[CATT]5–
8) (Figure 2) (Baugh et al., 2002). In addition, a specific 
single-nucleotide polymorphism (SNP) was identified at 
−173 (Donn et al., 2001), which affects the MIF mRNA 
expression level. From several lines of molecular-basis 
studies, it became evident that the polymorphism affects 
MIF promoter activity and regulates the expression of 
MIF mRNA (Hizawa et al., 2004).
Promoter Polymorphisms of the MIF Gene in a 
Japanese Population
We explored the relationship between promoter 
polymorphisms of the MIF gene and obesity in a 
Japanese population. In parallel with the available 
gene-related information from other laboratories, we 
found a significant relationship between MIF gene 
polymorphism and obesity in Japanese (Sakaue et al., 
2006). Briefly, 223 unrelated individuals were divided 
into three groups according to WHO definitions: lean 
(BMI<25 kg/m2), overweight (25>BMI>30 kg/m2) and 
obese (BMI>30 kg/m2). Polymorphism at −794 was 
analyzed by PCR, in which the PCR products and the 
GS-500 TAMRA size standard were analyzed. The sizes 
of the PCR products were 340, 344, 348 and 352 base 
pairs in length; these corresponded to 5-, 6-, 7-, and 
8-CATT repeats, respectively.
We clarified that the frequencies of the 5-, 6-, 7- and 
8-CATT alleles located at −794 of the MIF gene were 
40.6%, 41.3%, 17.8% and 0.2%, respectively. The 
transcriptional activity of the MIF promoter with the 
5-CATT repeat was lower than that with the other alleles 
at −794[CATT]5–8. We classified the subjects into two 
groups for further analysis; subjects with the 5-CATT 
allele (5/5 and 5/X) and those without the 5-CATT allele 
(X/X) (X indicates 6-, 7- or 8-CATT allele).
The X/X genotype was significantly more common in 
the obese subjects than in the lean or overweight groups. 
The subjects with the X/X genotype were at increased 
risk for obesity compared to those with the 5-CATT 
allele, adjusted by age and sex. The Japan Society for 
the Study of Obesity (JASSO) has defined BMIs of 
25 kg/m2 or higher as 'obese'. When the JASSO criterion 
was applied, the risk of obesity (BMI >25 kg/m2) in the 
subjects with the X/X genotype was also increased, with 
the odds ratio of 2.05. This finding indicates that the 
X-CATT allele is more frequent in obese subjects than 
in lean or overweight subjects. In contrast, SNPs at −
173 involved in the MIF mRNA expression level did not 
affect the adiposity of this population.
Perspective on MIF Studies with Regard to 
Functional Foods
In this review, we presented various physiologic 
and pathogenic characteristics of MIF, focusing on the 
expression and regulation of MIF mRNA in adipocytes 
and adipose tissues in relation to adiposity. From the 
available data, MIF expressed in muscle has a catabolic 
effect via the induction of 6-phosphofructo-2-kinase/
fructose-2, 6-bisphosphatase (Benigni et al., 2000). This 
report strongly supports the idea that MIF is profoundly 
linked to energy metabolism. Although it remains 
unclear whether this catabolic effect is physiologically 
Figure 2. Polymorphism of the promoter region of MIF gene. A tetranucleotide CATT repeat located at position -794 (-794[CATT]5–8) affects MIF 
mRNA expression, and is considered to be associated with adiposity. In addition, a specific single nucleotide polymorphism is identified at -173, 
which affects MIF mRNA expression level, but not adiposity.
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associated with the regulation of whole body weight, 
we speculate that MIF expression in adipose tissues is 
responsible for obesity through the catabolic effect of 
the MIF molecule. We observed a marked reduction of 
MIF contents in adipose tissues of obese rats (OLETF), 
as mentioned previously. It is of interest to investigate 
whether MIF is responsible for the adiposity of the 
obese rats in terms of energy consumption.
In conclusion, we are currently investigating the 
efficacy of foods such as onion, asparagus and broccoli 
on the amelioration of lifestyle diseases caused by 
visceral obesity. In the past few years, a number of 
studies have demonstrated that functional foods can 
ameliorate adiposity, resulting in the improvement of 
diabetes and hypertension. Based on our continued 
studies of MIF, we suspect that the measurement of 
MIF serum levels will be useful for the evaluation of 
the functions of foods, particularly in regard to diabetes 
and obesity. For an example, we measured the serum 
contents of MIF in prediabetic patients (HbA1c 6.0%
−6.5%), and found a significant increase compared to 
normal controls (Yabunaka, 2000). Likewise, elevated 
serum MIF has been found in American Pima Indians, 
who generally show a high incidence of type 2 diabetes. 
However, the serum MIF level would be affected by 
multiple factors, such as inflammatory disorders. Thus, 
any causal relationship between MIF and obesity 
should be carefully determined for each individual. 
Moreover, the polymorphism of MIF promoter gene 
analysis is considered to be useful for the prevention 
of lifestyle diseases through evidence-based nutrition 
education. MIF-based investigations of food, exercise, 
and prevention of disease are underway, and they may 
produce a novel scientific approach for food science.
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